Isotretinoin Labs, Lymphoma & Losing Sight: What’s the Real Risk?
Unable to add items
Add to basket failed.
Add to wishlist failed.
Failed to remove from Wish List.
Adding to library failed
Unable to follow podcast
Unable to unfollow podcast
Isotretinoin Labs, Lymphoma & Losing Sight: What’s the Real Risk?
-
Narrated by:
-
By:
Are we over-monitoring isotretinoin and overreacting to Dupixent safety signals? We unpack the evidence behind moving away from routine lab monitoring with isotretinoin, then tackle two of Dupixent’s most controversial reported adverse events: CTCL and vision loss. What’s a true safety signal, what’s association, and what should we actually tell our patients?
Skin in the Game delivers high-yield dermatology quick hits for busy clinicians.
Hosted by:
• Graham Litchman, DO, MS — Vivida Dermatology, Las Vegas, NV
• Diego Ruiz Dasilva, MD — Forefront Dermatology, Virginia Beach, VA
We read the research so you don’t have to.
For show notes and more information please visit our website at https://skininthegamepodcast.buzzsprout.com/
Disclaimer: This podcast is intended for educational purposes only and does not constitute medical advice. Views expressed are those of the hosts and do not necessarily reflect those of their employers or affiliated organizations.